The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH MM 2018 | Toxicity profile for CAR T-cells in multiple myeloma
Despite the very promising response rates seen with CAR T-cells in multiple myeloma (MM), the accompanying toxcities must also be considered. Speaking at the European School of Haematology (ESH) International Conference on Multiple Myeloma 2018, held in Mandelieu, France, Jesús Berdeja, MD, of the Sarah Cannon Center for Blood Cancer, Nashville, TN, discusses the toxicity profile of these agents in MM, namely cytokine release syndrome and neurotoxicity. Dr Berdeja highlights the frequency of such occurences, and the measures that can be taken to prevent and treat them.
